Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study
Year: 2018
Type: article
Study design: Observational Study
Abstract: Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with systemic inflammation proposed as a common mechanistic link. Fibrinogen has prognostic role in COPD. We aimed to determine whether aortic stiffness and quadriceps weakness are linked in COPD, and whether they are associated with the systemic inflammatory mediator—fibrinogen. Aortic pulse wave velocity (aPWV), quadriceps maximal volitional contraction (QMVC) force and fibrinogen were measured in 729 patients with stable, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II–IV COPD. The cardiovascular and muscular manifestations exist independently (P=0.22, χ2). Fibrinogen was not associated with aPWV or QMVC (P=0.628 and P=0.621, respectively), making inflammation, as measured by plasma fibrinogen, an unlikely common aetiological factor.
Source: Thorax
Authors: Divya Mohan, Julia R Forman, Matthew Allinder, Carmel M McEniery, Charlotte Emma Bolton, John R Cockcroft, William MacNee, Jonathan Fuld, Mellone Marchong, Nichola Sian Gale, Marie Fisk, Sridevi Nagarajan, Joseph Cheriyan, David A Lomas, Peter M A Calverley, Bruce E Miller, Ruth Tal-Singer, Ian B Wilkinson, Michael I Polkey
Institutions: Royal Brompton & Harefield NHS Foundation Trust, GlaxoSmithKline (United States), Imperial College London, University of Cambridge, Addenbrooke's Hospital, Cambridge Clinical Trials Unit, Nottingham University Hospitals NHS Trust, University of Nottingham, National Institute for Health and Care Research, Nottingham Biomedical Research Centre, Cardiff University, Centre for Inflammation Research, University of Edinburgh, University College London, University of Liverpool
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Royal Brompton and Harefield NHS Foundation Trust, National Institute for Health and Care Research, British Heart Foundation, University of Cambridge, Imperial College London, Heart Research Institute, Cambridge University Hospitals, Astellas Pharma, Promotion and Mutual Aid Corporation for Private Schools of Japan, Grifols, Medical Research Council, Innovate UK
OpenAlex ID: W2796170762